ロード中...
Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214
In the randomized, open-label, phase 3 CheckMate 214 trial, nivolumab plus ipilimumab (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 wk for four doses, then nivolumab 3 mg/kg every 2 wk) had superior efficacy over sunitinib (SUN; 50 mg once daily, 4 wk on, 2 wk off) in patients with untreated In...
保存先:
| 出版年: | Eur Urol |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7521478/ https://ncbi.nlm.nih.gov/pubmed/31732098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2019.10.025 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|